2 Scariest Dividend Stocks in Health Care Motley Fool Let's assume that multiple sclerosis drug daclizumab, developed with Biogen Idec (NASDAQ: BIIB ) , gains approval. Analysts estimate peak annual sales at $500 million on the high end. AbbVie splits profits equally with Biogen, so the drug would ... |
